Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Jun;4(11):225.
doi: 10.21037/atm.2016.05.48.

Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?

Satomi Watanabe  1 , Hidetoshi Hayashi  1 , Kazuhiko Nakagawa  1
Affiliations
Comment

Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?

Satomi Watanabe et al. Ann Transl Med. 2016 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: H Hayashi has received lecture fees from AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Bristol Myers Squibb, and Taiho Pharmaceutical Co. Ltd.; research funding from Ono Pharmaceutical Co. Ltd.; as well as advisory fees from AstraZeneca K.K., Boehringer Ingelheim Japan Inc., and Eli Lilly Japan K.K. K Nakagawa has received lecture fees and advisory fees from Chugai Pharmaceutical Co. Ltd., AstraZeneca K.K., and Nippon Boehringer Ingelheim Co., Ltd. S Watanabe has no conflicts of interest to declare.

Comment on

References

    1. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007;98:1817-24. 10.1111/j.1349-7006.2007.00607.x - DOI - PMC - PubMed
    1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57. 10.1056/NEJMoa0810699 - DOI - PubMed
    1. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-74. 10.1200/JCO.2010.33.4235 - DOI - PubMed
    1. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8. 10.1016/S1470-2045(09)70364-X - DOI - PubMed
    1. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8. 10.1056/NEJMoa0909530 - DOI - PubMed